Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex

Handbook of Clinical Neurology

Volumn 85, Issue , 2007, Pages 261-300

  Cinque, Paola ^a   Brew, Bruce J ^b   Gisslen, Magnus ^c   Hagberg, Lars ^c   Price, Richard W ^d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649348159     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)85017-2     Document Type: Review

References (390)

1. Abdulle S., Hagberg L., Svennerholm B., et al. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 16 (2002) 2145-2149
2. Abdulle S., Hagberg L., and Gisslen M. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Med 6 (2005) 164-169
3. Achim C.L., Heyes M.P., and Wiley C.A. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 91 (1993) 2769-2775
4. Adamson D.C., Wildemann B., Sasaki M., et al. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274 (1996) 1917-1921
5. Adamson D.C., McArthur J.C., Dawson T.M., et al. Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Mol Med 5 (1999) 98-109
6. Albright A.V., Shieh J.T., Itoh T., et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 73 (1999) 205-213
7. Alfano M., Sidenius N., Panzeri B., et al. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci USA 99 (2002) 8862-8867
8. Amadori A., De Rossi A., Gallo P., et al. Cerebrospinal fluid lymphocytes from HIV-infected patients synthesize HIV-specific antibody in vitro. J Neuroimmunol 18 (1988) 181-186
9. American Academy of Neurology. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 41 (1991) 778-785
10. Andersson L., Blennow K., Fuchs D., et al. Increased cerebrospinal fluid protein tau concentration in neuro-AIDS. J Neurol Sci 171 (1999) 92-96
11. Andersson L.M., Fredman P., Lekman A., et al. Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. AIDS Res Hum Retrovir 14 (1998) 1065-1069
12. Andersson L.M., Svennerholm B., Hagberg L., et al. Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation. J Med Virol 62 (2000) 9-13
13. Andersson M.A., Bergstrom T.B., Blomstrand C., et al. Increasing intrathecal lymphocytosis and immunoglobulin G production in neurologically asymptomatic HIV-1 infection. J Neuroimmunol 19 (1988) 291-304
14. Ando S., Toyoda Y., Nagai Y., et al. Alterations in brain gangliosides and other lipids of patients with Creutzfeldt-Jakob disease and subacute sclerosing panencephalitis (SSPE). Jpn J Exp Med 54 (1984) 229-234
15. Andreasen N., Sjogren M., and Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4 (2003) 147-155
16. Antinori A., Giancola M.L., Grisetti S., et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 16 (2002) 1867-1876
17. Antinori A., Perno C.F., Giancola M.L., et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 41 (2005) 1787-1793
18. Appleman M.E., Marshall D.W., Brey R.L., et al. Cerebrospinal fluid abnormalities in patients without AIDS who are seropositive for the human immunodeficiency virus. J Infect Dis 158 (1988) 193-199
19. 95-mediated apoptosis of uninfected astrocytes. J Leukoc Biol 68 (2000) 429-435
20. Arens M. Methods for subtyping and molecular comparison of human viral genomes. Clin Microbiol Rev 12 (1999) 612-626
21. Avison M.J., Nath A., Greene-Avison R., et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 10 (2004) 223-232
22. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 250 (2001) 91-104
23. Bajetto A., Bonavia R., Barbero S., et al. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 82 (2002) 1311-1329
24. Barlow K.L., Green J., and Clewley J.P. Viral genome characterisation by the heteroduplex mobility and heteroduplex tracking assays. Rev Med Virol 10 (2000) 321-335
25. Barron K.D. The microglial cell. A historical review. J Neurol Sci 134 Suppl (1995) 57-68
26. Berg D., Holzmann C., and Riess O. 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4 (2003) 752-762
27. Berger J.R., Avison M., Mootoor Y., et al. Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: preliminary observations. J Neurovirol 11 (2005) 557-562
28. Bernasconi S., Cinque P., Peri G., et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J Infect Dis 174 (1996) 1098-1101
29. Bestetti A., Presi S., Pierotti C., et al. Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol 10 Suppl 1 (2004) 52-57
30. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1 (2004) 213-225
31. Blond D., Raoul H., Le Grand R., et al. Nitric oxide synthesis enhances human immunodeficiency virus replication in primary human macrophages. J Virol 74 (2000) 8904-8912
32. Bolin L.M., Murray R., Lukacs N.W., et al. Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol 81 (1998) 49-57
33. Boufassa F., Bachmeyer C., Carre N., et al. Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. J Infect Dis 171 (1995) 1190-1195
34. Boven L.A., Gomes L., Hery C., et al. Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. J Immunol 162 (1999) 4319-4327
35. Bratanich A.C., Liu C., McArthur J.C., et al. Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity. J Neurovirol 4 (1998) 387-393
36. Brew B.J., Bhalla R.B., Paul M., et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 28 (1990) 556-560
37. Brew B.J., Bhalla R.B., Paul M., et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 6 (1992) 461-465
38. Brew B.J., Paul M.O., Nakajima G., et al. Cerebrospinal fluid HIV-1 p24 antigen and culture: sensitivity and specificity for AIDS-dementia complex. J Neurol Neurosurg Psychiatry 57 (1994) 784-789
39. 4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis 174 (1996) 294-298
40. Brew B.J., Pemberton L., Cunningham P., et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 175 (1997) 963-966
41. Brew B.J., Pemberton L., Blennow K., et al. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 65 (2005) 1490-1492
42. Brooke S.M., McLaughlin J.R., Cortopassi K.M., et al. Effect of GP120 on glutathione peroxidase activity in cortical cultures and the interaction with steroid hormones. J Neurochem 81 (2002) 277-284
43. Brugg B., Michel P.P., Agid Y., et al. Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem 66 (1996) 733-739
44. Buee L., Bussiere T., Buee-Scherrer V., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33 (2000) 95-130
45. Buffet R., Agut H., Chieze F., et al. Virological markers in the cerebrospinal fluid from HIV-1-infected individuals. AIDS 5 (1991) 1419-1424
46. Bukrinsky M.I., Nottet H.S., Schmidtmayerova H., et al. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med 181 (1995) 735-745
47. Chang L., Ernst T., St Hillaire C., et al. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 9 (2004) 431-440
48. Charcot J. Histologie de la sclérose en plaques. Gaz Hop (Paris) 41 (1868) 405-406 554, 557, 566
49. Cheng J., Zhou T., Liu C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263 (1994) 1759-1762
50. Chien J.W., Valdez H., McComsey G., et al. Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients. J Acquir Immune Defic Syndr 21 (1999) 277-280
51. Churchill M., Sterjovski J., Gray L., et al. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis 190 (2004) 2181-2186
52. Ciardi M., Sharief M.K., Noori M.A., et al. Intrathecal synthesis of interleukin-2 and soluble IL-2 receptor in asymptomatic HIV-1 seropositive individuals. Correlation with local production of specific IgM and IgG antibodies. J Neurol Sci 115 (1993) 117-122
53. Ciardi M., Sharief M.K., Thompson E.J., et al. High cerebrospinal fluid and serum levels of tumor necrosis factor-alpha in asymptomatic HIV-1 seropositive individuals. Correlation with interleukin-2 and soluble IL-2 receptor. J Neurol Sci 125 (1994) 175-179
54. Cinque P., and Linde A. CSF analysis in diagnosis of viral encephalitis and meningitis. In: Nath A., and Berger J.R. (Eds). Clinical Neurovirology (2003), Marcel Dekker, New York
55. Cinque P., Scarpellini P., Vago L., et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 11 (1997) 1-17
56. Cinque P., Vago L., Ceresa D., et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 12 (1998) 389-394
57. Cinque P., Vago L., Mengozzi M., et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12 (1998) 1327-1332
58. Cinque P., Presi S., Bestetti A., et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retrovir 17 (2001) 377-383
59. Cinque P., Nebuloni M., Santovito M.L., et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol 55 (2004) 687-694
60. Cinque P., Bestetti A., Marenzi R., et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 168 (2005) 154-163
61. Clements J.E., Babas T., Mankowski J.L., et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 186 (2002) 905-913
62. Coakley E., Petropoulos C.J., and Whitcomb J.M. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 18 (2005) 9-15
63. 8+ T cells. Science 270 (1995) 1811-1815
64. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 (1995) 483-489
65. Conant K., Garzino-Demo A., Nath A., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 95 (1998) 3117-3121
66. Conant K., McArthur J.C., Griffin D.E., et al. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 46 (1999) 391-398
67. Cota M., Kleinschmidt A., Ceccherini-Silberstein F., et al. Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. J Neurovirol 6 (2000) 75-83
68. Cotter R., Williams C., Ryan L., et al. Fractalkine (CX3CL1) and brain inflammation: implications for HIV-1-associated dementia. J Neurovirol 8 (2002) 585-598
69. Cunningham P.H., Smith D.G., Satchell C., et al. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14 (2000) 1949-1954
70. Cysique L.A., Brew B.J., Halman M., et al. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 39 (2005) 426-429
71. D'Aversa T.G., Yu K.O., and Berman J.W. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J Neurovirol 10 (2004) 86-97
72. Davidsson P., and Sjogren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 127 (2006) 133-137
73. de Gans J., Lange J.M., Derix M.M., et al. Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS 2 (1988) 37-40
74. De Luca A., Ciancio B.C., Larussa D., et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 59 (2002) 342-347
75. Desai A., Ravi V., Satishchandra P., et al. HIV antibody profiles in serum and CSF of patients with neurological disease can serve as predictors of outcome. J Neurol Neurosurg Psychiatry 68 (2000) 86-88
76. Dhawan S., Vargo M., and Meltzer M.S. Interactions between HIV-infected monocytes and the extracellular matrix: increased capacity of HIV-infected monocytes to adhere to and spread on extracellular matrix associated with changes in extent of virus replication and cytopathic effects in infected cells. J Leukoc Biol 52 (1992) 62-69
77. Di Stefano M., Sabri F., Leitner T., et al. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol 33 (1995) 352-355
78. Di Stefano M., Wilt S., Gray F., et al. HIV type 1 V3 sequences and the development of dementia during AIDS. AIDS Res Hum Retrovir 12 (1996) 471-476
79. Dorf M.E., Berman M.A., Tanabe S., et al. Astrocytes express functional chemokine receptors. J Neuroimmunol 111 (2000) 109-121
80. Eggers C., Hertogs K., Sturenburg H.J., et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17 (2003) 1897-1906
81. Ellis R.J., Hsia K., Spector S.A., et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 42 (1997) 679-688
82. Ellis R.J., Seubert P., Motter R., et al. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC). Neurosci Lett 254 (1998) 1-4
83. Ellis R.J., Gamst A.C., Capparelli E., et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54 (2000) 927-936
84. Ellis R.J., Moore D.J., Childers M.E., et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 59 (2002) 923-928
85. Ellis R.J., Childers M.E., Zimmerman J.D., et al. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. J Infect Dis 187 (2003) 1818-1821
86. Elovaara I., Seppala I., Poutiainen E., et al. Intrathecal humoral immunologic response in neurologically symptomatic and asymptomatic patients with human immunodeficiency virus infection. Neurology 38 (1988) 1451-1456
87. Elovaara I., Albert P.S., Ranki A., et al. HIV-1 specificity of cerebrospinal fluid and serum IgG, IgM, and IgG1-G4 antibodies in relation to clinical disease. J Neurol Sci 117 (1993) 111-119
88. Elovaara I., Poutiainen E., Lahdevirta J., et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch Neurol 51 (1994) 943-950
89. Elovaara I., Sabri F., Gray F., et al. Upregulated expression of Fas and Fas ligand in brain through the spectrum of HIV-1 infection. Acta Neuropathol (Berl) 98 (1999) 355-362
90. Eng L.F., and Ghirnikar R.S. GFAP and astrogliosis. Brain Pathol 4 (1994) 229-237
91. Engelhardt B., and Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26 (2005) 485-495
92. Enting R.H., Foudraine N.A., Lange J.M., et al. Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol 102 (2000) 216-221
93. Enting R.H., Prins J.M., Jurriaans S., et al. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis 32 (2001) 1095-1099
94. Erichsen D., Lopez A.L., Peng H., et al. Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol 138 (2003) 144-155
95. Espey M.G., Basile A.S., Heaton R.K., et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 58 (2002) 1439 author reply 1439-1440
96. Evers S., Rahmann A., Schwaag S., et al. Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. AIDS Res Hum Retrovir 20 (2004) 483-491
97. Ferrarese C., Riva R., Dolara A., et al. Elevated glutamate in the cerebrospinal fluid of patients with HIV dementia. JAMA 277 (1997) 630
98. Ferrarese C., Aliprandi A., Tremolizzo L., et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 57 (2001) 671-675
99. Fishman R.A. Cerebrospinal Fluid in Diseases of the Nervous System (1992), WB Saunders, Philadelphia, PA
100. Foudraine N.A., Hoetelmans R.M., Lange J.M., et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351 (1998) 1547-1551
101. Franciotta D.M., Melzi d'Eril G.L., Bono G., et al. Tumor necrosis factor alpha levels in serum and cerebrospinal fluid of patients with AIDS. Funct Neurol 7 (1992) 35-38
102. Fredrikson S., Eneroth P., and Link H. Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis. Clin Exp Immunol 67 (1987) 76-81
103. Fuchs D., Chiodi F., Albert J., et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 3 (1989) 285-288
104. Fuchs D., Forsman A., Hagberg L., et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 10 (1990) 599-603
105. Fuchs D., Gisslen M., Larsson M., et al. Increase of tryptophan in serum and in cerebrospinal fluid of patients with HIV infection during zidovudine therapy. Adv Exp Med Biol 398 (1996) 131-134
106. Furukawa Y., Nishi K., Kondo T., et al. Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci 111 (1992) 65-72
107. Gallo P., Frei K., Rordorf C., et al. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol 23 (1989) 109-116
108. Gallo P., Sivieri S., Rinaldi L., et al. Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. J Neurol Sci 126 (1994) 49-53
109. Garcia F., Alonso M.M., Romeu J., et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. J Acquir Immune Defic Syndr 25 (2000) 26-35
110. 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 129 (2002) 216-223
111. Garden G.A., Budd S.L., Tsai E., et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22 (2002) 4015-4024
112. Gardner J., and Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res 74 (2003) 801-806
113. Gelbard H.A., Nottet H.S., Swindells S., et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 68 (1994) 4628-4635
114. Gendelman H.E., Zheng J., Coulter C.L., et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 178 (1998) 1000-1007
115. Genis P., Jett M., Bernton E.W., et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 176 (1992) 1703-1718
116. Ghorpade A., Nukuna A., Che M., et al. Human immunodeficiency virus neurotropism: an analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J Virol 72 (1998) 3340-3350
117. Ghorpade A., Persidskaia R., Suryadevara R., et al. Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type 1-associated dementia. J Virol 75 (2001) 6572-6583
118. Giovannoni G., Miller R.F., Heales S.J., et al. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci 156 (1998) 53-58
119. Gisolf E.H., Enting R.H., Jurriaans S., et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 14 (2000) 1583-1589
120. Gisolf E.H., van Praag R.M., Jurriaans S., et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 25 (2000) 426-433
121. Gisslen M., Larsson M., Norkrans G., et al. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retrovir 10 (1994) 947-951
122. Gisslen M., Fredman P., Norkrans G., et al. Elevated cerebrospinal fluid sulfatide concentrations as a sign of increased metabolic turnover of myelin in HIV type I infection. AIDS Res Hum Retrovir 12 (1996) 149-155
123. Gisslen M., Hagberg L., Norkrans G., et al. Increased cerebrospinal fluid ganglioside GM1 concentrations indicating neuronal involvement in all stages of HIV-1 infection. J Neurovirol 3 (1997) 148-152
124. Gisslen M., Norkrans G., Svennerholm B., et al. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 175 (1997) 434-437
125. Gisslen M., Hagberg L., Fuchs D., et al. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 291-295
126. Gisslen M., Svennerholm B., Norkrans G., et al. Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis 32 (2000) 365-369
127. Gisslen M., Rosengren L., Hagberg L., et al. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther 2 (2005) 6
128. Gisslen M., Cinque P., Hagberg L., et al. High cerebrospinal fluid neurofilament protein levels in AIDS dementia complex. 13th Conference of Retrovirus and Opportunistic Infections. Denver, CO (2006)
129. Glass J.D., Wesselingh S.L., Selnes O.A., et al. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 43 (1993) 2230-2237
130. Glass J.D., Fedor H., Wesselingh S.L., et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38 (1995) 755-762
131. Gonzalez E., Rovin B.H., Sen L., et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 99 (2002) 13795-13800
132. Gonzalez-Scarano F., and Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22 (1999) 219-240
133. Gonzalez-Scarano F., and Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 5 (2005) 69-81
134. Gorry P.R., Bristol G., Zack J.A., et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 75 (2001) 10073-10089
135. Goudsmit J., de Wolf F., Paul D.A., et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 2 (1986) 177-180
136. Gray F., Chretien F., Vallat-Decouvelaere A.V., et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 62 (2003) 429-440
137. Green A.J., Giovannoni G., Miller R.F., et al. Cerebrospinal fluid S-100b concentrations in patients with HIV infection. AIDS 13 (1999) 139-140
138. Greenamyre J.T., and Porter R.H. Anatomy and physiology of glutamate in the CNS. Neurology 44 (1994) S7-S13
139. Griffin D.E. Cytokines in the brain during viral infection: clues to HIV-associated dementia. J Clin Invest 100 (1997) 2948-2951
140. Griffin D.E., McArthur J.C., and Cornblath D.R. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 41 (1991) 69-74
141. Griffin D.E., Wesselingh S.L., and McArthur J.C. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 35 (1994) 592-597
142. Grimaldi L.M., Castagna A., Lazzarin A., et al. Oligoclonal IgG bands in cerebrospinal fluid and serum during asymptomatic human immunodeficiency virus infection. Ann Neurol 24 (1988) 277-279
143. Grimaldi L.M., Martino G.V., Franciotta D.M., et al. Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol 29 (1991) 21-25
144. Gu L., Tseng S.C., and Rollins B.J. Monocyte chemoattractant protein-1. Chem Immunol 72 (1999) 7-29
145. Guillemin G.J., Croitoru-Lamoury J., Dormont D., et al. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 41 (2003) 371-381
146. Guillemin G.J., Wang L., and Brew B.J. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2 (2005) 16
147. Gunthard H.F., Havlir D.V., Fiscus S., et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 183 (2001) 1318-1327
148. Haas D.W., Johnson B.W., Spearman P., et al. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology 61 (2003) 1391-1396
149. Hagberg L. The clinical use of cerebrospinal fluid neopterin concentrations in central nervous system infections. Pteridins 6 (1995) 147-152
150. Hagberg L., Forsman A., Norkrans G., et al. Cytological and immunoglobulin findings in cerebrospinal fluid of symptomatic and asymptomatic human immunodeficiency virus (HIV) seropositive patients. Infection 16 (1988) 13-18
151. Hagberg L., Dotevall L., Norkrans G., et al. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 168 (1993) 1285-1288
152. Hagberg L., Fuchs D., Rosengren L., et al. Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol 102 (2000) 51-55
153. Harrigan P.R., Montaner J.S., Wegner S.A., et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15 (2001) 1671-1677
154. Harrington P.R., Haas D.W., Ritola K., et al. Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol 79 (2005) 7959-7966
155. Harrison J.K., Jiang Y., Chen S., et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95 (1998) 10896-10901
156. Haughey N.J., Cutler R.G., Tamara A., et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55 (2004) 257-267
157. Havlir D.V., Bassett R., Levitan D., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286 (2001) 171-179
158. He J., Chen Y., Farzan M., et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385 (1997) 645-649
159. Heidenreich F., Arendt G., Jander S., et al. Serum and cerebrospinal fluid levels of soluble intercellular adhesion molecule 1 (sICAM-1) in patients with HIV-1 associated neurological diseases. J Neuroimmunol 52 (1994) 117-126
160. Heizmann C.W., Fritz G., and Schafer B.W. S100 proteins: structure, functions and pathology. Front Biosci 7 (2002) d1356-d1368
161. Helke K.L., Queen S.E., Tarwater P.M., et al. 14-3-3 protein in CSF: an early predictor of SIV CNS disease. J Neuropathol Exp Neurol 64 (2005) 202-208
162. Hesselgesser J., Taub D., Baskar P., et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 8 (1998) 595-598
163. Heyes M.P., Brew B.J., Martin A., et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 29 (1991) 202-209
164. Heyes M.P., Brew B.J., Saito K., et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 40 (1992) 71-80
165. Heyes M.P., Saito K., Crowley J.S., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115 Pt 5 (1992) 1249-1273
166. Heyes M.P., Saito K., Lackner A., et al. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J 12 (1998) 881-896
167. Heyes M.P., Ellis R.J., Ryan L., et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. Brain 124 (2001) 1033-1042
168. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283 (2000) 2417-2426
169. Hollander H., and Levy J.A. Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid. Ann Intern Med 106 (1987) 692-695
170. Huang K.J., Alter G.M., and Wooley D.P. The reverse transcriptase sequence of human immunodeficiency virus type 1 is under positive evolutionary selection within the central nervous system. J Neurovirol 8 (2002) 281-294
171. Hughes E.S., Bell J.E., and Simmonds P. Investigation of population diversity of human immunodeficiency virus type 1 in vivo by nucleotide sequencing and length polymorphism analysis of the V1/V2 hypervariable region of env. J Gen Virol 78 Pt 11 (1997) 2871-2882
172. Ibanez A., Puig T., Elias J., et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 13 (1999) 1045-1049
173. Ikeda K., Akiyama H., Arai T., et al. Glial tau pathology in neurodegenerative diseases: their nature and comparison with neuronal tangles. Neurobiol Aging 19 (1998) S85-S91
174. Imamichi H., Crandall K.A., Natarajan V., et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 183 (2001) 36-50
175. Irani D.N., Anderson C., Gundry R., et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 59 (2006) 237-247
176. Izmailova E., Bertley F.M., Huang Q., et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 9 (2003) 191-197
177. Jana A., and Pahan K. Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci 24 (2004) 9531-9540
178. Jaranowska A., Bussolino F., Sogos V., et al. Platelet-activating factor production by human fetal microglia. Effect of lipopolysaccharides and tumor necrosis factor-alpha. Mol Chem Neuropathol 24 (1995) 95-106
179. Jiang Z.G., Piggee C., Heyes M.P., et al. Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol 117 (2001) 97-107
180. Johnston J.B., Zhang K., Silva C., et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 49 (2001) 230-241
181. Jones G., and Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis 21 (2006) 1-17
182. 95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373 (1995) 444-448
183. Kapural M., Krizanac-Bengez L., Barnett G., et al. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res 940 (2002) 102-104
184. Kaul M., Garden G.A., and Lipton S.A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410 (2001) 988-994
185. Kaul M., Zheng J., Okamoto S., et al. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12 Suppl 1 (2005) 878-892
186. Kelder W., McArthur J.C., Nance-Sproson T., et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 44 (1998) 831-835
187. Kerr S.J., Armati P.J., Pemberton L.A., et al. Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology 49 (1997) 1671-1681
188. Kerr S.J., Armati P.J., Guillemin G.J., et al. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12 (1998) 355-363
189. Keys B., Karis J., Fadeel B., et al. V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease. Virology 196 (1993) 475-483
190. Kitai R., Zhao M.L., Zhang N., et al. Role of MIP-1beta and RANTES in HIV-1 infection of microglia: inhibition of infection and induction by IFNbeta. J Neuroimmunol 110 (2000) 230-239
191. Kivisakk P., Trebst C., Liu Z., et al. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol 129 (2002) 510-518
192. Koenig S., Gendelman H.E., Orenstein J.M., et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233 (1986) 1089-1093
193. Kolb S.A., Sporer B., Lahrtz F., et al. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol 93 (1999) 172-181
194. Korber B.T., Kunstman K.J., Patterson B.K., et al. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 68 (1994) 7467-7481
195. Krivine A., Force G., Servan J., et al. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS dementia complex. J Neurovirol 5 (1999) 500-506
196. Kuiken C.L., Goudsmit J., Weiller G.F., et al. Differences in human immunodeficiency virus type 1 V3 sequences from patients with and without AIDS dementia complex. J Gen Virol 76 Pt 1 (1995) 175-180
197. Lafeuillade A., Poggi C., Pellegrino P., et al. HIV-1 replication in the plasma and cerebrospinal fluid. Infection 24 (1996) 367-371
198. Lafrenie R.M., Wahl L.M., Epstein J.S., et al. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol 157 (1996) 974-977
199. Lahrtz F., Piali L., Spanaus K.S., et al. Chemokines and chemotaxis of leukocytes in infectious meningitis. J Neuroimmunol 85 (1998) 33-43
200. Lane B.R., King S.R., Bock P.J., et al. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 307 (2003) 122-134
201. Lane T.E., Buchmeier M.J., Watry D.D., et al. Expression of inflammatory cytokines and inducible nitric oxide synthase in brains of SIV-infected rhesus monkeys: applications to HIV-induced central nervous system disease. Mol Med 2 (1996) 27-37
202. Langford T.D., Letendre S.L., Marcotte T.D., et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16 (2002) 1019-1029
203. Lanier E.R., Sturge G., McClernon D., et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 15 (2001) 747-751
204. Larsson M., Hagberg L., Norkrans G., et al. Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection. J Neurosci Res 23 (1989) 441-446
205. Laurenzi M.A., Siden A., Persson M.A., et al. Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system. Clin Immunol Immunopathol 57 (1990) 233-241
206. Lazzarin A., Castagna A., Cavalli G., et al. Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. J Clin Lab Immunol 38 (1992) 175-186
207. Lederman M.M., Georges D.L., Kusner D.J., et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J Acquir Immune Defic Syndr 7 (1994) 727-733
208. Letendre S., Marquie-Beck J., Singh K.K., et al. The monocyte chemotactic protein-1-2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol 157 (2004) 193-196
209. Letendre S.L., Lanier E.R., and McCutchan J.A. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J Infect Dis 180 (1999) 310-319
210. Letendre S.L., McCutchan J.A., Childers M.E., et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56 (2004) 416-423
211. Lewis L.L., Venzon D., Church J., et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 174 (1996) 16-25
212. Li W., Galey D., Mattson M.P., et al. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res 8 (2005) 119-134
213. Linde A., Klapper P.E., Monteyne P., et al. Specific diagnostic methods for herpesvirus infections of the central nervous system: a consensus review by the European Union Concerted Action on Virus Meningitis and Encephalitis. Clin Diagn Virol 8 (1997) 83-104
214. Lindsberg P.J., Yue T.L., Frerichs K.U., et al. Evidence for platelet-activating factor as a novel mediator in experimental stroke in rabbits. Stroke 21 (1990) 1452-1457
215. Liu J., Zhao M.L., Brosnan C.F., et al. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. J Immunol 157 (1996) 3569-3576
216. Liu M.T., and Lane T.E. Chemokine expression and viral infection of the central nervous system: regulation of host defense and neuropathology. Immunol Res 24 (2001) 111-119
217. Liuzzi G.M., Mastroianni C.M., Santacroce M.P., et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol 6 (2000) 156-163
218. Loetscher M., Gerber B., Loetscher P., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184 (1996) 963-969
219. Loetscher M., Loetscher P., Brass N., et al. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28 (1998) 3696-3705
220. Lu B., Rutledge B.J., Gu L., et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187 (1998) 601-608
221. Lucas C.V., Reaven E.P., Bensch K.G., et al. Immunoperoxidase staining of glial fibrillary acidic (GFA) protein polymerized in vitro: an ultramicroscopic study. Neurochem Res 5 (1980) 1199-1209
222. Lukes A., Mun-Bryce S., Lukes M., et al. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 19 (1999) 267-284
223. Malmestrom C., Haghighi S., Rosengren L., et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61 (2003) 1720-1725
224. Marconi S., De Toni L., Lovato L., et al. Expression of gangliosides on glial and neuronal cells in normal and pathological adult human brain. J Neuroimmunol 170 (2005) 115-121
225. Marra C.M., Lockhart D., Zunt J.R., et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 60 (2003) 1388-1390
226. Marshall D.W., Brey R.L., Cahill W.T., et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 45 (1988) 954-958
227. Martin C., Albert J., Hansson P., et al. Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels. J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998) 214-219
228. Martin-Garcia J., Kolson D.L., and Gonzalez-Scarano F. Chemokine receptors in the brain: their role in HIV infection and pathogenesis. AIDS 16 (2002) 1709-1730
229. Massaro A.R., and Tonali P. Cerebrospinal fluid markers in multiple sclerosis: an overview. Mult Scler 4 (1998) 1-4
230. Mastroianni C.M., Paoletti F., Valenti C., et al. Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry 55 (1992) 219-221
231. Matsuyama T., Hata R., Tagaya M., et al. Fas antigen mRNA induction in postischemic murine brain. Brain Res 657 (1994) 342-346
232. McArthur J.C., Cohen B.A., Farzedegan H., et al. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. Ann Neurol 23 Suppl (1988) S34-S37
233. McArthur J.C., Nance-Sproson T.E., Griffin D.E., et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology 42 (1992) 1707-1712
234. McArthur J.C., McClernon D.R., Cronin M.F., et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 42 (1997) 689-698
235. McArthur J.C., McDermott M.P., McClernon D., et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 61 (2004) 1687-1696
236. Melchjorsen J., Sorensen L.N., and Paludan S.R. Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. J Leukoc Biol 74 (2003) 331-343
237. Mellgren A., Antinori A., Cinque P., et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 10 (2005) 701-707
238. Mellors J.W., Rinaldo Jr. C.R., Gupta P., et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
239. Mengozzi M., De Filippi C., Transidico P., et al. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 93 (1999) 1851-1857
240. Meucci O., Fatatis A., Simen A.A., et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 95 (1998) 14500-14505
241. Meucci O., Fatatis A., Simen A.A., et al. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci USA 97 (2000) 8075-8080
242. Milstien S., Sakai N., Brew B.J., et al. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J Neurochem 63 (1994) 1178-1180
243. Mogi M., Harada M., Kondo T., et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 220 (1996) 195-198
244. Mondino A., and Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25 (2004) 450-455
245. Monteiro de Almeida S., Letendre S., Zimmerman J., et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 169 (2005) 144-152
246. Montine T.J., Beal M.F., Cudkowicz M.E., et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 52 (1999) 562-565
247. Morris L., Silber E., Sonnenberg P., et al. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis 177 (1998) 473-476
248. Murphy P.M., Baggiolini M., Charo I.F., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52 (2000) 145-176
249. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
250. Navia B.A., Jordan B.D., and Price R.W. The AIDS dementia complex: I. Clinical features. Ann Neurol 19 (1986) 517-524
251. Neuenburg J.K., Sinclair E., Nilsson A., et al. HIV-producing T cells in cerebrospinal fluid. J Acquir Immune Defic Syndr 37 (2004) 1237-1244
252. Neuenburg J.K., Cho T.A., Nilsson A., et al. T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. J Acquir Immune Defic Syndr 39 (2005) 16-22
253. Neuenburg J.K., Furlan S., Bacchetti P., et al. Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS 19 (2005) 1351-1359
254. Nottet H.S., and Gendelman H.E. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol Today 16 (1995) 441-448
255. Nottet H.S., Jett M., Flanagan C.R., et al. A regulatory role for astrocytes in HIV-1 encephalitis. An overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-alpha by activated HIV-1-infected monocytes is attenuated by primary human astrocytes. J Immunol 154 (1995) 3567-3581
256. Nottet H.S., Persidsky Y., Sasseville V.G., et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 156 (1996) 1284-1295
257. Nykjaer A., Moller B., Todd R.F., et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol 152 (1994) 505-516
258. Ogden F., DeCoster M.A., and Bazan N.G. Recombinant plasma-type platelet-activating factor acetylhydrolase attenuates NMDA-induced hippocampal neuronal apoptosis. J Neurosci Res 53 (1998) 677-684
259. Ohagen A., Devitt A., Kunstman K.J., et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol 77 (2003) 12336-12345
260. Peeters M.F., Colebunders R.L., Van den Abbeele K., et al. Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood. J Med Virol 47 (1995) 92-96
261. Pemberton L.A., and Brew B.J. Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex. J Clin Virol 22 (2001) 249-253
262. Pereira C.F., Middel J., Jansen G., et al. Enhanced expression of fractalkine in HIV-1 associated dementia. J Neuroimmunol 115 (2001) 168-175
263. Perelson A.S., Neumann A.U., Markowitz M., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996) 1582-1586
264. Perrella O., Guerriero M., Izzo E., et al. Interleukin-6 and granulocyte macrophage-CSF in the cerebrospinal fluid from HIV infected subjects with involvement of the central nervous system. Arq Neuropsiquiatr 50 (1992) 180-182
265. Perrella O., Carreiri P.B., Perrella A., et al. Transforming growth factor beta-1 and interferon-alpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load?. Eur Cytokine Netw 12 (2001) 51-55
266. Peterson P.K., Gekker G., Hu S., et al. Microglial cell upregulation of HIV-1 expression in the chronically infected promonocytic cell line U1: the role of tumor necrosis factor-alpha. J Neuroimmunol 41 (1992) 81-87
267. Pettoello-Mantovani M., Casadevall A., Kollmann T.R., et al. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339 (1992) 21-23
268. Petzold A., Eikelenboom M.J., Gveric D., et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125 (2002) 1462-1473
269. Petzold A., Jenkins R., Watt H.C., et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett 336 (2003) 167-170
270. Pierotti C., Lillo F., Vago L., et al. Cerebrospinal Fluid HIV-1 p24 Antigen versus HIV-1 RNA as Low Cost Marker Supporting the Diagnosis of HIV-Associated CNS Disease. HIV Infection and the Central Nervous System, Developed and Resource Limited Settings (2005), Frascati, Italy
271. Pilcher C.D., Shugars D.C., Fiscus S.A., et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 15 (2001) 837-845
272. Polis M.A., Suzman D.L., Yoder C.P., et al. Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. AIDS 17 (2003) 1167-1172
273. Power C., and Patel K.D. Neurolipidomics: an inflammatory perspective on fat in the brain. Neurology 63 (2004) 608-609
274. Power C., McArthur J.C., Johnson R.T., et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 68 (1994) 4643-4649
275. Price R.W. The two faces of HIV infection of cerebrospinal fluid. Trends Microbiol 8 (2000) 387-391
276. Price R.W., and Deeks S.G. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: clinical and pathogenetic implications for the central nervous system. J Neurovirol 10 Suppl 1 (2004) 44-51
277. Price R.W., Paxinos E.E., Grant R.M., et al. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15 (2001) 1251-1259
278. Pulliam L., Clarke J.A., McGrath M.S., et al. Monokine products as predictors of AIDS dementia. AIDS 10 (1996) 1495-1500
279. Qin S., Rottman J.B., Myers P., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101 (1998) 746-754
280. Reddy R.T., Achim C.L., Sirko D.A., et al. Sequence analysis of the V3 loop in brain and spleen of patients with HIV encephalitis. AIDS Res Hum Retrovir 12 (1996) 477-482
281. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310 (2001) 173-186
282. Reid M.C., Lachs M.S., and Feinstein A.R. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 274 (1995) 645-651
283. Reinhart T.A. Chemokine induction by HIV-1: recruitment to the cause. Trends Immunol 24 (2003) 351-353
284. Resnick L., Berger J.R., Shapshak P., et al. Early penetration of the blood-brain barrier by HIV. Neurology 38 (1988) 9-14
285. Respess R.A., Cachafeiro A., Withum D., et al. Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J Clin Microbiol 43 (2005) 506-508
286. Rho M.B., Wesselingh S., Glass J.D., et al. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun 9 (1995) 366-377
287. Richman D.D. Principles of HIV resistance testing and overview of assay performance characteristics. Antivir Ther 5 (2000) 27-31
288. Rieckmann P., Nunke K., Burchhardt M., et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 47 (1993) 133-140
289. Rimaniol A.C., Zylberberg H., Rabian C., et al. Imbalance between IL-1 and IL-1 receptor antagonist in the cerebrospinal fluid of HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 16 (1997) 340-342
290. Ritola K., Pilcher C.D., Fiscus S.A., et al. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol 78 (2004) 11208-11218
291. Ritola K., Robertson K., Fiscus S.A., et al. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 79 (2005) 10830-10834
292. Robertson K.R., Robertson W.T., Ford S., et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36 (2004) 562-566
293. Rosengren L.E., Lycke J., and Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 133 (1995) 61-65
294. Rosengren L.E., Karlsson J.E., Karlsson J.O., et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67 (1996) 2013-2018
295. Rothermundt M., Peters M., Prehn J.H., et al. S100B in brain damage and neurodegeneration. Microsc Res Tech 60 (2003) 614-632
296. Royal III W., Selnes O.A., Concha M., et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) p24 antigen levels in HIV-1-related dementia. Ann Neurol 36 (1994) 32-39
297. Sabri F., De Milito A., Pirskanen R., et al. Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. J Neuroimmunol 114 (2001) 197-206
298. Sabri F., Titanji K., De Milito A., et al. Astrocyte activation and apoptosis: their roles in the neuropathology of HIV infection. Brain Pathol 13 (2003) 84-94
299. Sacktor N., Haughey N., Cutler R., et al. Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol 157 (2004) 176-184
300. Saha R.N., and Pahan K. Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia. J Neurochem 86 (2003) 1057-1071
301. Sala S., Spudich S., Presi S., et al. Comparison of HIV-1 Pol Gene Sequences between CSF and Plasma shows Increasing Compartmentalization of Replication with Disease Stage and AIDS Dementia Complex. HIV Infection and the Central Nervous System, Developed and Resource Limited Settings (2005), Frascati, Italy
302. Sanders V.J., Pittman C.A., White M.G., et al. Chemokines and receptors in HIV encephalitis. AIDS 12 (1998) 1021-1026
303. Sarchielli P., Galli F., Floridi A., et al. Relevance of protein nitration in brain injury: a key pathophysiological mechanism in neurodegenerative, autoimmune, or inflammatory CNS diseases and stroke. Amino Acids 25 (2003) 427-436
304. Sasseville V.G., Newman W.A., Lackner A.A., et al. Elevated vascular cell adhesion molecule-1 in AIDS encephalitis induced by simian immunodeficiency virus. Am J Pathol 141 (1992) 1021-1030
305. Sasseville V.G., Smith M.M., Mackay C.R., et al. Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. Am J Pathol 149 (1996) 1459-1467
306. Schmid P., Conrad A., Syndulko K., et al. Quantifying HIV-1 proviral DNA using the polymerase chain reaction on cerebrospinal fluid and blood of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr 7 (1994) 777-788
307. Schmidtmayerova H., Nottet H.S., Nuovo G., et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci USA 93 (1996) 700-704
308. Schupbach J. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. AIDS Rev 4 (2002) 83-92
309. Sethi K.K., and Naher H. Elevated titers of cell-free interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome. Immunol Lett 13 (1986) 179-184
310. Sevigny J.J., Albert S.M., McDermott M.P., et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63 (2004) 2084-2090
311. 8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis 189 (2004) 2202-2212
312. Shaheen F., and Collman R.G. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 17 (2004) 7-16
313. Shaskan E.G., Brew B.J., Rosenblum M., et al. Increased neopterin levels in brains of patients with human immunodeficiency virus type 1 infection. J Neurochem 59 (1992) 1541-1546
314. Shaskan E.G., Thompson R.M., and Price R.W. Undetectable tumor necrosis factor-alpha in spinal fluid from HIV-1-infected patients. Ann Neurol 31 (1992) 687-689
315. Shaunak S., Albright R.E., Klotman M.E., et al. Amplification of HIV-1 provirus from cerebrospinal fluid and its correlation with neurologic disease. J Infect Dis 161 (1990) 1068-1072
316. Shaunak S., Albright R.E., and Bartlett J.A. Amplification of human immunodeficiency virus provirus from cerebrospinal fluid: results of long-term clinical follow-up. J Infect Dis 164 (1991) 818
317. Sidenius N., Sier C.F., Ullum H., et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96 (2000) 4091-4095
318. Sidenius N., Nebuloni M., Sala S., et al. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol 157 (2004) 133-139
319. Siliciano J.D., and Siliciano R.F. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 54 (2004) 6-9
320. Singer E.J., Syndulko K., Fahy-Chandon B.N., et al. Cerebrospinal fluid p24 antigen levels and intrathecal immunoglobulin G synthesis are associated with cognitive disease severity in HIV-1. AIDS 8 (1994) 197-204
321. Sippy B.D., Hofman F.M., Wallach D., et al. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995) 511-521
322. Smith D.G., Guillemin G.J., Pemberton L., et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol 7 (2001) 56-60
323. Smith M.O., Heyes M.P., and Lackner A.A. Early intrathecal events in rhesus macaques (Macaca mulatta) infected with pathogenic or nonpathogenic molecular clones of simian immunodeficiency virus. Lab Invest 72 (1995) 547-558
324. Sonnerborg A.B., von Stedingk L.V., Hansson L.O., et al. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 3 (1989) 277-283
325. Sonnerborg A.B., von Sydow M.A., Forsgren M., et al. Association between intrathecal anti-HIV-1 immunoglobulin G synthesis and occurrence of HIV-1 in cerebrospinal fluid. AIDS 3 (1989) 701-705
326. Sonnerborg A., Johansson B., and Strannegard O. Detection of HIV-1 DNA and infectious virus in cerebrospinal fluid. AIDS Res Hum Retrovir 7 (1991) 369-373
327. 87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Immunobiology 199 (1998) 152-162
328. Sporer B., Paul R., Koedel U., et al. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J Infect Dis 178 (1998) 854-857
329. Sporer B., Koedel U., Goebel F.D., et al. Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients. AIDS Res Hum Retrovir 16 (2000) 221-226
330. Sporer B., Kastenbauer S., Koedel U., et al. Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res Hum Retrovir 19 (2003) 111-116
331. Sporer B., Missler U., Magerkurth O., et al. Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker for HIV-associated dementia. Infection 32 (2004) 20-23
332. Sporer B., Koedel U., Popp B., et al. Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients. J Neuroimmunol 163 (2005) 190-194
333. Spudich S.S., Huang W., Nilsson A.C., et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 191 (2005) 890-898
334. Spudich S.S., Nilsson A.C., Lollo N.D., et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 5 (2005) 98
335. Staprans S., Marlowe N., Glidden D., et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 13 (1999) 1051-1061
336. Stellbrink H.J., Eggers C., van Lunzen J., et al. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 11 (1997) 1655-1657
337. Steuler H., Munzinger S., Wildemann B., et al. Quantitation of HIV-1 proviral DNA in cells from cerebrospinal fluid. J Acquir Immune Defic Syndr 5 (1992) 405-408
338. Steuler H., Storch-Hagenlocher B., and Wildemann B. Distinct populations of human immunodeficiency virus type 1 in blood and cerebrospinal fluid. AIDS Res Hum Retrovir 8 (1992) 53-59
339. Stevens G., Rekhviashvili N., Scott L.E., et al. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol 43 (2005) 857-861
340. Stingele K., Haas J., Zimmermann T., et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 56 (2001) 355-361
341. 4 and chemokine coreceptors. Lab Invest 83 (2003) 1787-1798
342. Stone T.W., Mackay G.M., Forrest C.M., et al. Tryptophan metabolites and brain disorders. Clin Chem Lab Med 41 (2003) 852-859
343. Strain M.C., Letendre S., Pillai S.K., et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 79 (2005) 1772-1788
344. Streit W.J., Graeber M.B., and Kreutzberg G.W. Functional plasticity of microglia: a review. Glia 1 (1988) 301-307
345. Studahl M., Rosengren L., Gunther G., et al. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol 247 (2000) 636-642
346. Stuve O., Dooley N.P., Uhm J.H., et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40 (1996) 853-863
347. Stuyver L., Wyseur A., Rombout A., et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41 (1997) 284-291
348. Sui Y., Potula R., Dhillon N., et al. Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. Am J Pathol 164 (2004) 1557-1566
349. Suryadevara R., Holter S., Borgmann K., et al. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44 (2003) 47-56
350. Svenningsson A., Hansson G.K., Andersen O., et al. Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. Ann Neurol 34 (1993) 155-161
351. Tambussi G., Gori A., Capiluppi B., et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 30 (2000) 962-965
352. Tanaka M., Itai T., Adachi M., et al. Downregulation of Fas ligand by shedding. Nat Med 4 (1998) 31-36
353. Tang Y.W., Huong J.T., Lloyd Jr. R.M., et al. Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma. J Clin Microbiol 38 (2000) 4637-4639
354. Tashima K.T., Flanigan T.P., Kurpewski J., et al. Discordant human immunodeficiency virus type 1 drug resistance mutations, including K103N, observed in cerebrospinal fluid and plasma. Clin Infect Dis 35 (2002) 82-83
355. Taub D.D., Lloyd A.R., Conlon K., et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177 (1993) 1809-1814
356. Teunissen C.E., Dijkstra C., and Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4 (2005) 32-41
357. Thompson K.A., McArthur J.C., and Wesselingh S.L. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Ann Neurol 49 (2001) 745-752
358. Tong N., Perry S.W., Zhang Q., et al. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol 164 (2000) 1333-1339
359. Torre D., Zeroli C., Ferraro G., et al. Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system. Scand J Infect Dis 24 (1992) 787-791
360. Towfighi A., Skolasky R.L., St Hillaire C., et al. CSF soluble Fas correlates with the severity of HIV-associated dementia. Neurology 62 (2004) 654-656
361. Trebst C., Staugaitis S.M., Tucky B., et al. Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol Appl Neurobiol 29 (2003) 584-595
362. Trujillo J.R., Navia B.A., Worth J., et al. High levels of anti-HIV-1 envelope antibodies in cerebrospinal fluid as compared to serum from patients with AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 12 (1996) 19-25
363. Tsoukas C.M., and Bernard N.F. Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 7 (1994) 14-28
364. Tyor W.R., Glass J.D., Griffin J.W., et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol 31 (1992) 349-360
365. Vago L., Nebuloni M., Bonetto S., et al. Rantes distribution and cellular localization in the brain of HIV-infected patients. Clin Neuropathol 20 (2001) 139-145
366. Valle M., Price R.W., Nilsson A., et al. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 127 (2004) 1047-1060
367. van den Brande G., Marquie-Beck J., Capparelli E., et al. Kaletra independently reduces HIV replication in cerebrospinal fluid. 12th Conference on Retrovirus and Opportunistic Infections, Boston, MA (2005)
368. van Marle G., and Power C. Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant?. J Neurovirol 11 (2005) 107-128
369. van Marle G., Henry S., Todoruk T., et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 329 (2004) 302-318
370. Van Wielink G., McArthur J.C., Moench T., et al. Intrathecal synthesis of anti-HIV IgG: correlation with increasing duration of HIV-1 infection. Neurology 40 (1990) 816-819
371. Vandamme A.M., Houyez F., Banhegyi D., et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther 6 (2001) 21-39
372. Venturi G., Catucci M., Romano L., et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 181 (2000) 740-745
373. Vesce S., Bezzi P., Rossi D., et al. HIV-1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid. FEBS Lett 411 (1997) 107-109
374. Viviani B., Corsini E., Binaglia M., et al. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience 107 (2001) 51-58
375. Wakabayashi H., Yano M., Tachikawa N., et al. Increased concentrations of 14-3-3 epsilon, gamma and zeta isoforms in cerebrospinal fluid of AIDS patients with neuronal destruction. Clin Chim Acta 312 (2001) 97-105
376. Wesselingh S.L., Power C., Glass J.D., et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 33 (1993) 576-582
377. Wetzel M.A., Steele A.D., Henderson E.E., et al. The effect of X4 and R5 HIV-1 on C, C-C, and C-X-C chemokines during the early stages of infection in human PBMCs. Virology 292 (2002) 6-15
378. Wildemann B., Haas J., Ehrhart K., et al. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients. Neurology 43 (1993) 2659-2663
379. Wiley C.A., Achim C.L., Schrier R.D., et al. Relationship of cerebrospinal fluid immune activation associated factors to HIV encephalitis. AIDS 6 (1992) 1299-1307
380. Wilt S.G., Milward E., Zhou J.M., et al. In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 37 (1995) 381-394
381. Winkler F., Kastenbauer S., Koedel U., et al. Role of the urokinase plasminogen activator system in patients with bacterial meningitis. Neurology 59 (2002) 1350-1355
382. Wirleitner B., Schroecksnadel K., Winkler C., et al. Neopterin in HIV-1 infection. Mol Immunol 42 (2005) 183-194
383. Wong J.K., Ignacio C.C., Torriani F., et al. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 71 (1997) 2059-2071
384. Woodman S.E., Benveniste E.N., Nath A., et al. Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes. J Neurovirol 5 (1999) 678-684
385. Xia M.Q., and Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 5 (1999) 32-41
386. Xia M.Q., Bacskai B.J., Knowles R.B., et al. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 108 (2000) 227-235
387. Zhang K., McQuibban G.A., Silva C., et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 6 (2003) 1064-1071
388. Zhao J., Lopez A.L., Erichsen D., et al. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J Neurochem 88 (2004) 169-180
389. Zheng J., Thylin M.R., Ghorpade A., et al. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuroimmunol 98 (1999) 185-200
390. Zink M.C., Coleman G.D., Mankowski J.L., et al. Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 184 (2001) 1015-1021